Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer remains a leading cause of mortality worldwide, with high morbidity.
• Emerging drug resistance and lack of targeted therapy in cancer treatment pose significant challenges.
• Opioid growth factor (OGF), or Met-enkephalin, is an endogenous pentapeptide with demonstrated antitumor properties.

Purpose of the Study:

• To review the structure-activity relationship of OGF and its analogues.
• To highlight OGF derivatives with potential anticancer, analgesic, and immunomodulatory activities.
• To explore the potential of OGF as a safe and effective adjunct in cancer therapy.

Main Methods:

• Review of existing literature on OGF and its analogues.
• Analysis of structure-activity relationships.
• Evaluation of preclinical and clinical trial data regarding OGF efficacy and safety.

Main Results:

• OGF therapy, alone or with chemotherapy, has shown to be safe, non-toxic, and effective in reducing tumor size.
• OGF derivatives exhibit analgesic and immunomodulatory properties.
• Certain OGF analogues demonstrate blood-brain barrier penetration, suggesting potential for central nervous system applications.

Conclusions:

• Met-enkephalin and its analogues represent promising candidates for novel, non-toxic anticancer drugs with analgesic activity.
• Further preclinical and clinical studies are warranted to fully explore the therapeutic potential of OGF in oncology.
• OGF-based therapies may enhance chemotherapy efficacy and improve the quality of life for cancer patients.